about
PET/CT imaging of Mycobacterium tuberculosis infectionImaging fungal infections in childrenAntimicrobial peptides: their role as infection-selective tracers for molecular imagingProstate Cancer: Epigenetic Alterations, Risk Factors, and TherapyNovel Radiolabeled Bisphosphonates for PET Diagnosis and Endoradiotherapy of Bone MetastasesSynthesis, 68Ga-radiolabeling, and preliminary in vivo assessment of a depsipeptide-derived compound as a potential PET/CT infection imaging agent.Imaging latent tuberculosis infection with radiolabeled nitroimidazoles.Association between plasma homocysteine and myocardial SPECT abnormalities in patients referred for suspected myocardial ischaemiaPositron emission tomography in patients suffering from HIV-1 infection.68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients.PET/CT scanning with a high HIV/AIDS prevalence.Nuclear medicine imaging in tuberculosis using commercially available radiopharmaceuticals.Gallium-68: a systematic review of its nononcological applications.FDG-PET imaging in HIV infection and tuberculosis.Radiolabelled probes targeting tumor hypoxia for personalized medicine.Development and prospects of dedicated tracers for the molecular imaging of bacterial infections.Advances in imaging of tuberculosis: the role of ¹⁸F-FDG PET and PET/CT.Role of nuclear medicine in neuroHIV: PET, SPECT, and beyond.Effect of AIDS on women who have sex-determined health issues.Appropriate indications for positron emission tomography/computed tomography, 2015.Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.Reversible mycordial perfusion defects in patients not suffering from obstructive epicardial coronary artery disease as assessed by coronary angiography: a review of the literature.Gallium-68 PET: A Powerful Generator-based Alternative to Infection and Inflammation Imaging.Appropriate indications for positron emission tomography/computed tomography: College of Nuclear Physicians of the Colleges of Medicine of South Africa.F-18 FDG PET/CT imaging of cardiac and vascular inflammation and infection.A randomized-controlled study of a modified technique to reduce extracardiac activity in myocardial perfusion imaging.The Role of Nuclear Medicine in the Staging and Management of Human Immune Deficiency Virus Infection and Associated Diseases.Preclinical Assessment of a 68Ga-DOTA-Functionalized Depsipeptide as a Radiodiagnostic Infection Imaging Agent.Metabolic Imaging of Infection.The role of F-18 FDG PET/CT in evaluating the impact of HIV infection on tumor burden and therapy outcome in patients with Hodgkin lymphoma.Rheumatic fever: a forgotten but still existing cause of fever of unknown origin detected on FDG PET/CT.Synthesis, in vitro evaluation, and 68 Ga-radiolabeling of CDP1 toward PET/CT imaging of bacterial infection.Comparison of rubidium-82 myocardial blood flow quantification with coronary calcium score for evaluation of coronary artery stenosis.213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer.Impact of FDG PET on the management of TBC treatment. A pilot study.Combined 18F-fluoride and 18F-FDG PET/CT: a response based on actual data from prospective studies.Peptide synthesis, characterization and ⁶⁸Ga-radiolabeling of NOTA-conjugated ubiquicidin fragments for prospective infection imaging with PET/CT.What impact can fluorine-18 fluorodeoxyglucose PET/computed tomography have on HIV/AIDS and tuberculosis pandemic?Evaluating the possible role of 68Ga-citrate PET/CT in the characterization of indeterminate lung lesions.Renal osteodystrophy presenting as a metabolic superscan on F-18 FDG PET/CT: A case report.
P50
Q26748493-92C9FCB9-F312-41FB-9B7D-7CAC59FBEF20Q26766376-BFF799B6-D345-4FE2-B701-45C73420DB61Q27014021-7D613F24-006D-4499-AB36-FDB6CC0AAE09Q28073470-B09E115F-BB14-423E-9774-ADD222B9E87BQ33851523-4FC98BB9-9A80-4527-AA0B-CC4DB948F3F9Q35073029-4DC83C04-5786-4F42-8180-5CCB4C8D6C25Q36764339-31A86DCD-93CA-4ABE-BC9F-FF5E968EB893Q37073336-0BC66125-6B6F-4551-83ED-211F02063284Q37436060-CDB1CD92-DB0C-446A-88BE-A559326C9E14Q37662685-57DC68A3-37FE-46CD-8053-EAC77EC37D4CQ37846339-21B2A95A-F3CF-45FB-87B9-E6C43386265CQ37994085-3219156B-06BA-4426-A6B1-6F49470DA6C3Q38118121-B9B6ACF7-30E4-454F-9487-1DD96D3A5EAEQ38125724-C2F5711B-2FCD-4C39-A9D0-946E57396977Q38136365-AB8CDB59-FA31-4AB9-B904-380CE077C380Q38160587-2819C3DA-51AE-41CB-88B9-1E94DF55F60AQ38194853-5B1A849D-AEAB-4D22-BD1B-113B76013916Q38208168-9EF22DF0-E4B2-4855-80F4-C2983E7FF6B5Q38264251-0E70D18F-551E-46ED-9D1D-7A5AE7F5EEE5Q38705050-7BE953DC-B87F-43AF-9994-974843AF7B38Q38709405-A9C22CF7-0EB8-4F3E-A9EE-FD50E53A2E94Q38786105-CA796DA2-A73B-4E8D-98D7-044619181E7FQ38935097-94E8A1BB-37C2-403C-85E6-DEEBA155F653Q38935899-813F1284-F00A-49B4-9C3D-B8C0077DA5C4Q38950827-B64A4273-5142-47EB-98F1-87D5F490EF50Q39281720-01837DC9-4939-41F2-803E-3C793A415E4BQ39339439-F5B9CF9D-C24E-4584-BDD4-71270E8299DDQ40081284-7D7FF6E8-2332-422A-B502-912559C5658FQ40089198-BBF7A593-41BD-474B-9C80-4C4B43D865EEQ40153947-857230D4-6D40-41B4-9B3B-7F90417AE5DEQ40176077-1E754ADB-CF0E-4893-BCFF-4C23E48D35EDQ40284352-CA3401BA-0AFB-42A9-B5AA-7D40FE55C205Q40409990-3A5BD589-146E-4B4E-B805-2F2FF8B1BDB5Q41856358-9906D3D9-91FE-4429-AD5B-3DBF3CBDE94AQ43159626-5B4C3A4A-9409-4C39-AFB8-C7B906F28113Q44002717-9DEC6901-7B8F-4B4C-8BFE-A11268B8011DQ44078790-55680D98-020C-4E77-85D3-A4167CD4C3A8Q46055844-6033E297-B247-4430-972C-CF843C426701Q46153146-E12F4F21-D541-441B-A6C1-7B3FFEA214C8Q46201766-D92BBEBE-F1E6-4C0B-AC9F-5699800D1802
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mike M Sathekge
@ast
Mike M Sathekge
@en
Mike M Sathekge
@es
Mike M Sathekge
@nl
Mike M Sathekge
@sl
type
label
Mike M Sathekge
@ast
Mike M Sathekge
@en
Mike M Sathekge
@es
Mike M Sathekge
@nl
Mike M Sathekge
@sl
altLabel
Machaba Michael Sathekge
@en
prefLabel
Mike M Sathekge
@ast
Mike M Sathekge
@en
Mike M Sathekge
@es
Mike M Sathekge
@nl
Mike M Sathekge
@sl
P106
P21
P31
P496
0000-0002-2806-0625